Datapoint: Pfizer Scores Atopic Dermatitis Approval for Cibinqo

The FDA last week approved Pfizer’s JAK1 inhibitor Cibinqo for the treatment of moderate to severe atopic dermatitis in adults who have not been able to adequately manage the disease with other medications. The more limited scope of the approval is good news for Sanofi and Regeneron, whose monoclonal antibody Dupixent currently dominants the atopic dermatitis space. The drug currently holds covered or better status for 92% of all insured lives under the pharmacy benefit. 39% of lives have preferred access to Dupixent.

SOURCE: MMIT Analytics, as of 1/19/22

0

0

0 Comments

0

0

• Datapoint